KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Fulgent Genetics (FLGT) Accumulated Depreciation & Amortization (2016 - 2026)

Fulgent Genetics' Accumulated Depreciation & Amortization history spans 12 years, with the latest figure at $61.3 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 11.74% to $61.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $61.3 million, a 11.74% increase, with the full-year FY2025 number at $57.9 million, up 12.06% from a year prior.
  • Accumulated Depreciation & Amortization hit $61.3 million in Q1 2026 for Fulgent Genetics, up from $57.9 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for FLGT hit a ceiling of $124.6 million in Q4 2022 and a floor of $23.2 million in Q1 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $52.2 million across 5 years, with a median of $49.7 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 534.92% in 2022 and later plummeted 58.57% in 2023.
  • Tracing FLGT's Accumulated Depreciation & Amortization over 5 years: stood at $124.6 million in 2022, then plummeted by 58.57% to $51.6 million in 2023, then increased by 0.15% to $51.7 million in 2024, then grew by 12.06% to $57.9 million in 2025, then grew by 5.81% to $61.3 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for FLGT at $61.3 million in Q1 2026, $57.9 million in Q4 2025, and $54.2 million in Q3 2025.